Design Therapeutics, Inc. (DSGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DSGN Stock Price Chart Interactive Chart >
DSGN Price/Volume Stats
|Current price||$12.94||52-week high||$28.49|
|Prev. close||$11.95||52-week low||$9.61|
|Day high||$13.19||Avg. volume||161,275|
|50-day MA||$13.97||Dividend yield||N/A|
|200-day MA||$15.60||Market Cap||721.82M|
Design Therapeutics, Inc. (DSGN) Company Bio
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Most Popular Stories View All
DSGN Latest News Stream
|Loading, please wait...|
DSGN Latest Social Stream
View Full DSGN Social Stream
Latest DSGN News From Around the Web
Below are the latest news stories about Design Therapeutics Inc that investors may wish to consider to help them evaluate DSGN as an investment opportunity.
CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 11:20 a.m. ET. A live webcast will be available in the inves
Design Therapeutics (DSGN) announced the appointment of Jae Kim, M.D., as the companys new Chief Medical Officer.Before joining Design (DSGN), Dr
CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer. Dr. Kim will play a pivotal role in leading clinical strategy and development, including the company’s first clinical trial planned to begin in the first half of 2022. “I am thrilled to welcome Jae to Design, particularly as we prepare t
Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN ) with a Sell rating and a $10 price target. The analyst Madhu Kumar has caution about the Company''s lead indication of Friedreich ataxia. Natural history studies provide little support that differences in FXN levels will shift the FA disease course. At the same time, high-dose nicotinamide has already achieved clinically meaningful FXN induction with the minimal observed change in Full story available on Benzinga.com
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
DSGN Price Returns